48th week of 2014 patent applcation highlights part 38 |
Patent application number | Title | Published |
20140348729 | PROCESS FOR SEPARATING AND RECOVERING METALS - A process for treating spent catalyst containing heavy metals, e.g., Group VIB metals and Group VIII metals is provided. In one embodiment after deoiling, the spent catalyst is treated with an ammonia leach solution under conditions sufficient to dissolve the group VIB metal and the Group VIII metal into the leaching solution, forming a leach slurry. After solid-liquid separation to recover a leach solution, chemical precipitation and solids repulping is carried out to obtain an effluent stream containing ammonium sulfate (Amsul), ammonium sulfamate, Group VB, Group VIB and Group VIII metals. Following sulfidation, the Group VIII metal is fully removed and Group VB and Group VI metals are partially removed from the Amsul stream. In the additional steps of oxydrolysis and iron precipitation, an effective amount of ferric ion at a pre-select pH is added to form insoluble complexes with the Group VB and Group VIB metals, which upon liquid-solid separation produces an effluent ammonium sulfate stream containing less than 10 ppm each of the Group VB and Group VIB metals. | 2014-11-27 |
20140348730 | HYDROGEN CHLORIDE REMOVAL PROCESS - A hydrogen chloride removal process includes (i) contacting in a reactor an aqueous solution, which includes one or more Fe | 2014-11-27 |
20140348731 | METHOD FOR PRODUCING COBALT SULFATE - Provided is a method for producing cobalt sulfate, wherein, on the occasion of separating an acidic solution containing calcium, magnesium and sodium as impurities from a cobalt chloride solution by solvent extraction, when a diluent is added to the extractant to be used to dilute the extractant by 10% to 30% by volume; in Step 1, the operational pH is maintained in the range of 4.0 to 5.0 and the liquid volume ratio of organic phase/liquid phase is maintained in the range of 5.0 to 7.0; in Step 2, the operational pH is maintained in the range of 4.0 to 4.5 and the liquid volume ratio of organic phase/liquid phase is maintained in the range of 5.0 to 10.0; and in Step 3, the pH is maintained in the range of 0.5 to 1.0. | 2014-11-27 |
20140348732 | OPERATING METHOD IN HYDROMETALLURGY OF NICKEL OXIDE ORE - It is an object to provide a method for producing magnesium oxide by which magnesium oxide being high in purity and low in impurity content can be produced simply and efficiently from a sulfuric acid solution containing magnesium and calcium such as waste water. In the present invention, calcium is precipitated as calcium sulfate and separated by concentrating a sulfuric acid solution containing magnesium and calcium, and magnesium is precipitated as magnesium sulfate and separated by further concentrating the solution resulting from the separation of calcium. The separated magnesium sulfate is roasted together with a reductant, so that magnesium oxide and sulfur dioxide are obtained. The resulting magnesium oxide is washed to produce magnesium oxide with high purity. | 2014-11-27 |
20140348733 | CONTINUOUS FE(III) PRODUCTION AT ATMOSPHERIC PRESSURES - A method oxidizes ferrous iron to ferric iron. The method includes providing a liquid, which includes the ferrous iron, and a gas, which includes an oxidizing agent, such as oxygen and/or chlorine; providing two separate mixes, with both mixes including the gas and the liquid; and colliding the separate mixes, thereby obtaining the ferric iron. | 2014-11-27 |
20140348734 | METHOD FOR EXTRACTION OF LITHIUM FROM LITHIUM BEARING SOLUTION - A method of extracting lithium from a lithium bearing solution and specifically, economically extracting lithium from a lithium bearing solution comprising the steps of: adding a nucleus particle to a lithium bearing solution; and precipitating the dissolved lithium in the lithium bearing solution as lithium phosphate by adding a phosphorous supplying material to the lithium bearing solution including the nucleus particle is provided. | 2014-11-27 |
20140348735 | PREPARATION OF AN AQUEOUS REAGENT FOR THE ABSORPTION OR DESTRUCTION OF POLLUTANTS - Process for treating a medium by the removal or destruction of one or more undesired substances present in said medium, comprising combining hydrogen peroxide and alkali hydroxide in an aqueous solution to form superoxide, and bringing the resultant superoxide-containing solution into contact with said medium. The process is useful for the destruction of halogenated organic pollutants and also for carbon dioxide removal from flue gases. The process can also be applied for soil remediation. | 2014-11-27 |
20140348736 | ADSORBENT MATERIAL, PROCESS FOR ITS PREPARATION AND USE THEREOF - The present invention discloses an adsorbent material having the following formula: Cu | 2014-11-27 |
20140348737 | CYCLONE REACTOR AND METHOD FOR PRODUCING USABLE BY-PRODUCTS USING CYCLONE REACTOR - A method for producing a usable by-product in a cyclone reactor. The method comprises introducing a reactant into a housing of the reactor through an inlet; using a burner to combust a first portion of the reactant in an exothermic reaction provided in a flame zone near a center of the housing; consuming a second portion of the reactant in an endothermic reaction near an outer wall of the housing to produce the by-product as part of a slag layer; and removing the slag layer including the by-product though an outlet in the housing; wherein the endothermic reaction takes place at a temperature of at least 1600° C. | 2014-11-27 |
20140348738 | Process for preparing sodium bicarbonate particles - A process for preparing sodium bicarbonate particles, comprising the steps of: (a) adding at least one alkali metal carbonate to an aqueous solution in order to form an aqueous composition; wherein the alkali metal carbonate comprises sodium carbonate and wherein the aqueous composition comprises at least one polycarboxylic acid and/or the salts thereof, in an amount of at least 200 ppm based on the weight of the aqueous composition; and (b) precipitating solid particles comprising sodium bicarbonate crystals and separating said sodium bicarbonate particles from the aqueous composition, in order to obtain sodium bicarbonate particles and an aqueous mother liquor. | 2014-11-27 |
20140348739 | METHOD AND SYSTEMS FOR FORMING CARBON NANOTUBES - Systems and a method for forming carbon nanotubes are described. A method includes forming carbon nanotubes in a reactor, using a Bosch reaction. The carbon nanotubes are separated from a reactor effluent to form a waste gas stream. The feed gas, a dry waste gas stream, or both, are heated with waste heat from the waste gas stream. The waste gas stream is chilled in an ambient temperature heat exchanger to condense water vapor, forming a dry waste gas stream. | 2014-11-27 |
20140348740 | DEVICE FOR MIXING AND COOLING TWO REACTIVE LIQUIDS AND METHOD OF MAKING PEROXOMONOSULPHURIC ACID WITH THE DEVICE - A device for mixing and cooling two reactive liquids, comprising a bundle type heat exchanger with parallel tubes, a head space open to one end of all tubes, a first inlet to the head space for introducing a first liquid and a second inlet to the head space with a multitude of nozzles for introducing a second liquid, the nozzles being located within the head space and oriented to direct the introduced liquid transverse to the axis of the tubes of the tube bundle, is useful for making peroxomonosulphuric acid from 85 to 98% by weight sulphuric acid introduced into the first inlet of the device and 50 to 80% by weight aqueous hydrogen peroxide introduced into the second inlet of the device. | 2014-11-27 |
20140348741 | PROCESS AND APPARATUS FOR TREATING A SULPHUR-CONTAINING OFF-GAS FROM A SULPHUR RECOVERY SYSTEM - The invention relates to a process and apparatus for recovering sulfur ( | 2014-11-27 |
20140348742 | HYDROGEN PRODUCTION METHOD BY MULTI-STEP COPPER-CHLORINE THERMOCHEMICAL CYCLE - The present invention discloses a method for thermochemical production of hydrogen and oxygen from water by a low temperature, multi-step, closed, cyclic copper-chlorine (Cu—Cl) process involving the reactions of copper and chlorine compounds. A method for production of hydrogen via Cu—Cl thermochemical cycle consists of four thermal reactions and one electrochemical reaction and one unit operation. The cycle involves six steps: (1) hydrogen production step; (2) copper production step; (3) drying step; (4) hydrogen chloride production step; (5) decomposition step; (6) oxygen production step. The net reaction of the sequential process is the decomposition of water into hydrogen and oxygen. The methods for production of copper oxide which comprises contacting copper chloride particles with superheated steam and production of oxygen comprises reaction of copper oxide with dry chlorine as a part of hydrogen production by thermochemical Copper-Chlorine (Cu—Cl) cycle. The reactions are performed in a flow through type quartz reactor as fixed bed type at high temperature and atmospheric pressure. | 2014-11-27 |
20140348743 | MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) - The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually. | 2014-11-27 |
20140348744 | COMPOSITIONS AND METHODS FOR REGULATING CANCER-RELATED SIGNALING PATHWAYS - The use of luteinizing hormone receptor (LHR) as a treatment target in cancer is provided. Data demonstrates that LHR plays an important role in androgen synthesis and signaling pathways critical for prostate cancer progression. When LHR is silenced, there is a significant downregulation of androgen receptor (AR) mRNA and protein expression with a subsequent suppression of PSA expression. Data suggesting that the LH-LHR signaling cascade may be an upstream and viable therapeutic target in castration-resistant prostate cancer (CRPC) is presented. | 2014-11-27 |
20140348745 | CHIMERIC THERAPEUTIC ANTI - CD37 ANTIBODIE HH1 - The present invention relates to chimieric or humanized antibodies derived from the mouse monoclonal antibody HH1. The applications of the present invention include therapeutic applications in which pharmaceutical compositions comprising the antibodies of the present invention or radioimmunoconjugates hereof are used for treating B-cell malignancies. | 2014-11-27 |
20140348746 | 4,4-DISUBSTITUTED CYCLOHEXYL BRIDGED HEPTAMETHINE CYANINE DYES AND USES THEREOF - The invention relates to a family of compounds that comprise fluorescent cyanine dyes. The compounds are near infrared absorbing heptamethine cyanine dyes with a 4,4-disubstituted cyclohexyl ring as part of the polymethine chromophore. The compounds are generally hydrophilic and can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications. | 2014-11-27 |
20140348747 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION - Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide. | 2014-11-27 |
20140348748 | BETA-AMYLOID IMAGING AGENTS, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF - Derivatives of benzothiazolylbenzeneamines useful as imaging agents for nuclear imaging such as positron emission tomography of beta-amyloids are described. Methods of detecting amyloid using the compounds are described. Also disclosed is a radiolabeling method for selected compounds. | 2014-11-27 |
20140348749 | IDENTIFICATION AND TREATMENT OF TUMORS SENSITIVE TO GLUCOSE LIMITATION - In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to glucose restriction are provided. In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to OXPHOS inhibitors are provided. In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to biguanides are provided. In some aspects, methods of identifying subjects with cancer who are candidates for treatment with an OXPHOS inhibitor are provided. In some aspects, methods of identifying subjects with cancer who are candidates for treatment with a biguanide are provided. In some aspects, methods of treating subjects with cancers that are sensitive to glucose restriction are provided. | 2014-11-27 |
20140348750 | HYPERSPECTRAL IMAGING FOR EARLY DETECTION OF ALZHEIMER'S DISEASE - Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD. | 2014-11-27 |
20140348751 | Method for Testing and Treating Delayed Food Allergies - A method for testing, treating, and preventing delayed food allergies includes: receiving detailed symptom, medical, and dietary histories from a patient; formulating a combination of one or more food extracts at selected concentrations for sublingual administration over a trial period; determining whether the patient's symptoms have improved, worsened, or had no change, in response to the administration of the combination; and altering the combination in response to whether the patient's symptoms have improved, worsened, or not changed, so as to induce immune system food tolerance. | 2014-11-27 |
20140348752 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS - The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided. | 2014-11-27 |
20140348753 | HETEROCYCLE-FUNCTIONALIZED LUMINOGENS EXHIBITING AGGREGATION-INDUCED EMISSION - The development of a series of fluorescent materials including heterocycle-functionalized luminogens with aggregation-induced/enhanced emission (AIE/AEE), long wavelength emission, and high solid state fluorescence quantum efficiency is contemplated. The described fluorescent materials are promising candidates in selective luminescence-based chemosensor for Hg | 2014-11-27 |
20140348754 | Method of Delivering Therapeutics and Imaging Agents to the Brain by Nanoparticles that Cross the Blood Brain Barrier - Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to the external surface of the nanoparticle core. Additionally, the linker can promote disassociation of the ligand from the nanoparticle when inside a cell. | 2014-11-27 |
20140348755 | TARGETED NANOPARTICLES JOINED TO REPORTER MOLECULES THROUGH MULTIPLE MECHANISMS - Nanoparticles, such as liposomes etc., containing multiple reporter molecules, e.g. dyes, fluorophores, FRET pairs, semiconductor nanocrystals, fluorescent chelates, chelate complexes, coordination complexes, mass tags, Raman tags, lanthanides, enzymes, enzymatic substrates, etc., through a combination of multiple physical and/or chemical interactions are disclosed. The reporter molecules are associated with the nanoparticle in at least two different ways, i.e. through different mechanisms. The nanoparticle is targeted through a targeting agent such as an antibody, an antibody fragment, a nucleotide, a peptide, an aptamer, biotin, avidin, or a ligand. The nanoparticles are useful in bioassays or imaging where an analyte is to be detected by binding of the nanoparticle to the analyte and detection of a signal from the reporter molecules. | 2014-11-27 |
20140348756 | WATER-FREE FORMULATIONS HAVING A COOLING EFFECT - Compositions for personal hygiene or body care, in particular deodorants, antiperspirants, massage fluids, foot care agents, shaving aids, or oral care agents, which preferably are present as a spray, including 0-7 wt % of free water, at least one cosmetic oil that is liquid under normal conditions, an oily extract from the leaves of Rumex acetosa, and in addition to the aforementioned components at least one cooling agent, wherein the amount specifications are relative to the weight of the composition without taking into account any present propellant. | 2014-11-27 |
20140348757 | SHELLAC BASED SPRAYABLE SUNSCREEN - A sprayable alcohol-based sunscreen comprises an alcohol carrier, at least one sunscreen additive, and a film forming polymer comprising shellac. | 2014-11-27 |
20140348759 | Structured Surfactant Suspending Systems - A structured surfactant system with a very high degree of clarity. The system comprises water and a mixture of at least one surfactant having a HLB (Hydrophilic Lipophilic Balance) value of less than 10, and at least one surfactant having an HLB value of 10 or greater. The structured surfactant system forms multilamellar vesicles and has suspending properties without added electrolytes, carbohydrates, or polymeric thickeners. This makes the structured surfactant system particularly useful in personal care compositions. | 2014-11-27 |
20140348760 | ORAL CARE COMPOSITIONS - Described herein are oral care compositions comprising (i) a magnesium alkali metal silicate complex clay, and (ii) an orally acceptable anionic polymer, in a dentifrice base, which compositions are useful for alleviating dental sensitivity. Also provided for, are methods of making and using the compositions described herein. | 2014-11-27 |
20140348761 | SOLUBILIZED MAGNOLOL ANALOGS - A composition comprising a solubilized magnolol analog comprising at least one magnolol analog chosen from propyl magnolol, isopropyl magnolol, butyl magnolol, and isobutyl magnolol, and PPG-1-PEG-9 lauryl glycol ether. These solubilized analogs are useful in personal care, oral care, and home care compositions to provide anti-bacterial activity and reducing the expression of pro-inflammatory mediators. | 2014-11-27 |
20140348762 | DIAGNOSTIC METHODS - Described herein are methods for identifying a mammal having a heightened susceptibility to enamel erosion, together with kits therefor and uses and methods related thereto. | 2014-11-27 |
20140348763 | COMPOSITIONS CONTAINING ISOSORBIDE MONOESTER AND ALCOHOLS THAT CONTAIN AT LEAST ONE AROMATIC GROUP - Compositions comprising isosorbide monoesters and alcohols comprising at least one aromatic group | 2014-11-27 |
20140348764 | Methods of Blocking Ultraviolet Radiation and Promoting Skin Growth Using Terpenes and Terpenoids - The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to rejuvenate the skin and increase the protective layer against irradiation by ultraviolet radiation (UVR). More specifically it provides terpenes and terpenoids as ingredients that work as persistent UVR blockers. Terpenes and terpenoid compounds support the growth of skin, skin tissue and keratinocytes and additional UVR-blocking by reason of increased stratum corneum thickness and loricrin content. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 6 mg to about 600 mg per kilogram of body weight per day effective to stimulate growth of the skin layer and prevent damage from ultraviolet radiation (UVR). | 2014-11-27 |
20140348765 | Water-in-Oil Emulsified Skin Cosmetic - The present invention relates to a water-in-oil emulsified skin cosmetic comprising the following ingredients (a) through (e): | 2014-11-27 |
20140348766 | BIOACTIVE COMPOSITONS HAVING SKIN ANTI AGING ACTIVITY - The present invention relates to bioactive compositions comprising blends of camellia and feverfew serum fractions and/or kelp and parsley serum fractions. | 2014-11-27 |
20140348767 | AMPHOTERIC ION-TYPE BASIC AMINO ACID DERIVATIVE - Provided is a compound capable of gelling various aqueous compositions containing salt, acid and the like. | 2014-11-27 |
20140348768 | ACRIDINEDIONE DERIVATIVES FOR TREATING PIGMENTATION DISORDERS AND AGEING OF THE SKIN - The present invention relates to a compound of general formula (I) in which: —R | 2014-11-27 |
20140348769 | COMPOSITIONS CONTAINING SILICON RESIN, OIL AND GELLING AGENT - The invention relates to a composition, especially a cosmetic composition, comprising at least one silicon resin comprising at least one T unit, at least one phenylated oil and at least one gelling agent, as well as to methods of using such compositions. | 2014-11-27 |
20140348770 | DEFORMATION MEANS FOR KERATIN-CONTAINING FIBERS CONVEYS STRONG HOLD AND NATURAL APPEARANCE - Agents for treating keratin-containing fibers, in particular human hair, comprising a cosmetically acceptable carrier, and: (a) at least one strengthening anionic copolymer, comprising at least one structural unit of formula (I) and at least one structural unit of formula (II) and at least one structural unit of formula (III), and (b) at least one polymer comprising at least one structural unit of formula (M1), produce an excellent hold of a shape imposed on the fibers, e.g. a hairstyle. The keratin-containing fibers are given a pronounced shine and feel soft. | 2014-11-27 |
20140348771 | HAIR CARE COMPOSITIONS - The invention relates to hair care compositions comprising an effective amount of a condensation polymer having at least one, optionally quarternized or protonated, dialkylamide end-group connected through the polymer backbone to a unit derived from an alkylamide, the connection comprising at least one ester linkage. | 2014-11-27 |
20140348772 | PRODUCTION OF HYDROGELS BY MEANS OF DIELS-ALDER REACTION - The present invention is directed to hydrogels and their preparation by cross-linking macromonomers by means of Diels-Alder reaction. The hydrogels described in the invention, which can gel in situ, are suitable, inter alia, as biomaterial for medical applications, as scaffolding material for living cells and as carrier system for the controlled release of drugs. | 2014-11-27 |
20140348773 | ARTIFICIAL BONE IMPLANTS, OR BONE GRAFTS, OF POLYMERIC COMPOSITES WITH BONE FORMING PROPERTIES - The present invention relates to methods for providing polymeric composites with bone forming, such as with osteogenic and/or osteoinductive and/or osteoconductive, properties. The present invention further relates to polymeric composites provided by the present method and the use of thereof for bone implants, or grafts, specifically the use thereof for orbital floor reconstruction. Specifically, the present invention relates to methods for providing a composite with bone forming properties, the method comprises the steps of: a) providing a liquid, or liquefied, polymeric composition of homopolymers or copolymers of 1,3-trimethylene carbonate (TMC); b) adding to said liquid, or liquefied, polymeric composition one or more agents with osteogenic and/or osteoinductive and/or osteoconductive properties thereby providing a dispersion of said agents in said liquid or liquefied polymeric composition; and c) crosslinking the product obtained, thereby providing a composite with bone forming properties. | 2014-11-27 |
20140348774 | METHOD FOR TREATING WOUNDS AND TISSUE REPAIR - The present inventions relate to a number of fields including wound healing, a waterless antibacterial disinfectant, a surgical scrub, insect repellant, and methods of treating traumatic injuries, particularly those on the battlefield where there is a need to stabilize the patient and prevent infection. | 2014-11-27 |
20140348775 | WOUND TREATMENT DRUG FOR EXTERNAL USE - [Problems] The objective is to provide a new low-toxic drug for external use for intractable diseases, such as erosion, decubitus, and skin ulcer, that prevents cicatrization and reduces iodine accumulation on wound surfaces with sufficiently promoting healing. | 2014-11-27 |
20140348776 | ADDITIVES TO RESIN COMPOSITIONS FOR IMPROVED IMPACT STRENGTH AND FLEXIBILITY - The invention provides a composition comprising: (a) about 0% to 99% by weight of at least one resin wherein the resin is selected from the group consisting of epoxy, latex, polyurethane, polyurea, polyspartic, or alkyd resins; (b) about 1%-99% by weight of tristyrenated phenol or distyrenated phenol; and (c) optionally about 2% to 98% by weight of an additional solvent. | 2014-11-27 |
20140348777 | Polysorbitol-Based Osmotically Active Transporter and Gene Therapy Using Same - The present invention relates to a biodegradable polysorbitol-based osmotically active transporter (PSOAT) and gene therapy using the same as a gene carrier. The biodegradable polysorbitol-based osmotically active transporter (PSOAT) of the present invention includes a sorbitol skeleton, which imparts an osmotic pressure to the cell membrane to improve membrane permeability, thereby exhibiting remarkably improved transfection efficiency. Further, the polysorbitol-based osmotically active transporter of the present invention exhibits high DNA binding ability, effectively protects DNA from nuclease, exhibits physicochemical properties suitable for use as a gene carrier, and has very low cytotoxicity in vitro and in vivo, thereby capable of being used as a gene carrier for gene therapy. | 2014-11-27 |
20140348778 | REVERSE THERMAL GELS AND THEIR USE IN CELL THERAPY - Methods are disclosed herein for increasing survival of transplanted cells, either in vitro or in vivo. In additional embodiments, methods are disclosed for treating a subject with a spinal cord injury or a neurodegenerative disorder. The methods include administering to a subject a therapeutically effective amount of cells, such as bone marrow stromal cells, and a therapeutically effective amount of a reverse thermal gel composition. The reverse thermal gel compositing includes a triblock copolymer, or pharmaceutically acceptable salt thereof, having the structure B-A-B in which A is one of a polyurethane or poly(ester urethane) group that comprises one or more pendant active groups, blocked active groups or active agents and B is a hydrophilic block, wherein the composition is a gel at 25° C.-40° C. and a liquid solution at a lower temperature. | 2014-11-27 |
20140348779 | OPHTHALMIC COMPOSITION - A topical ophthalmic composition for treatment of dry eye is disclosed. In preferred embodiments, the composition comprises as active ingredients hyaluronic acid or a pharmaceutically acceptable salt thereof and polyvinylpyrrolidine. In other embodiments of the invention, the composition additionally comprises polyvinyl alcohol. Methods of preparation of the composition are disclosed, as well as methods for use of the composition in the treatment of dry eye. | 2014-11-27 |
20140348780 | Method of Enhanced Antibiotic Activity Via Chemotaxis - Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to a pharmaceutical compositions which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as | 2014-11-27 |
20140348781 | CONJUGATES OF GM-CSF AND IL-9, COMPOSITIONS AND METHODS RELATED THERETO - In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-9 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-9 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids. | 2014-11-27 |
20140348782 | VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS - A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions. | 2014-11-27 |
20140348783 | VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS - A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions. | 2014-11-27 |
20140348784 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS IN PATHOLOGICAL LESIONS - Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-γ (IFN-γ), Tumor Necrosis Factor α (TNFα) or Tissue Factor protein (which may be truncated). | 2014-11-27 |
20140348785 | NEUTRALIZING GP41 ANTIBODIES AND THEIR USE - Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection. | 2014-11-27 |
20140348786 | BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY - β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided. | 2014-11-27 |
20140348787 | Methods and Compositions for Treating Ear Infections - Compositions and methods for treating ear infections are disclosed. More specifically, these methods may refer to treatment of internal otitis using an otic composition, such as otic gel for animals and humans. Poloxamer otic gel may be in liquid state at room temperature and may change to gel at about temperature (64° F.) as poloxamer otic gel reaches body temperature, because of the thermo-reversible properties. Consequently, poloxamer otic gel may be an effective treatment in animals and humans, where poloxamer otic gel may reach otitis affected site and remain there for a longer period of time. Additionally, poloxamer otic gel may include APIs such as antifungals, antibiotics and corticosteroids, among others. Furthermore, poloxamer otic gel may be instilled inside the ear, employing calibrated delivery device into the vertical ear canal in order to reach the horizontal ear canal, without puncturing the tympanic membrane. | 2014-11-27 |
20140348788 | METHOD TO MODULATE PIGMENTATION PROCESS IN THE MELANOCYTES OF SKIN - The invention describes a method to modulate melanosome maturation process in melanocytes. Further, it describes a method to reversibly alter the process of pigmentation in the human epidermal skin. The method targets melanosome maturation and its transfer to keratinocytes, which are key processes involved in the pigmentation for its potential use in predictable and controlled regulation of pigmentation in human skin. | 2014-11-27 |
20140348789 | TARGETED MUTANT ALPHA-HELICAL BUNDLE CYTOKINES - This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified α-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified α-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors. | 2014-11-27 |
20140348790 | ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME - The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors. | 2014-11-27 |
20140348791 | MODIFIED ADENOVIRAL VECTORS AND METHODS OF TREATMENT USING SAME - The present invention relates to recombinant adenovirus serotype 5 (Ad5) vectors which harbor chimeric capsid proteins including substitutions of the corresponding regions from adenovirus serotypes having a lower seroprevalence relative to Ad5. In particular, the chimeric capsid includes modifications of both the adenoviral hexon and fiber proteins. The invention also provides methods for the treatment of diseases or disorders caused by infective agent(s) by administering the adenoviral vector(s) to a subject (e.g., a mammal, such as a human). | 2014-11-27 |
20140348792 | METHODS TO REDUCE POLYPOSIS AND COLORECTAL CANCER - Methods for reducing or inhibiting polyposis or colorectal cancer are provided. The methods comprise administering to a mammal a bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods find use in treating or preventing a variety of polyp-related disorders, for example, treating or Lynch syndrome, familial adenomatous polyposis, and colorectal cancer. | 2014-11-27 |
20140348793 | Method of Treatment - The present invention relates generally to a method of regenerating the hippocampus in a mammal and agents for use therein. More particularly, the present invention provides a method of regenerating the hippocampus in a mammal by administering a sub-population of neural crest stem cells. The method of the present invention is useful in the treatment of conditions characterised by a defective hippocampus, such as neuropsychiatric disorders. | 2014-11-27 |
20140348794 | AAV4 VECTOR AND USES THEREOF - The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles. | 2014-11-27 |
20140348795 | NUTRITIONAL BEVERAGE POWDER AND METHOD OF MAKING SAME - A nutraceutical compound designed to promote cellular health, cleanse and replenish a body's gastro-intestinal tract and system, balance a body's natural defense system, keep the immune system high, and keep intestinal bacteria feeding on the correct enzymes is disclosed. More specifically, a nutraceutical compound that includes glutathione, carnosin, B vitamins, amino acids, probiotics, aloe vera, chlorella, spirulina, fruit powders, superfoods, and minerals is disclosed. | 2014-11-27 |
20140348796 | BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS - This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions. | 2014-11-27 |
20140348797 | METHOD FOR INHIBITING PROLIFERATION OF PLANT PATHOGENIC MICROBE USING COLLIMONAS BACTERIUM - To provide a method for inhibiting the proliferation of a plant pathogenic bacterium. A method for inhibiting the proliferation of a plant pathogenic bacterium, including culturing a microorganism having an ability to inhibit the proliferation of a plant pathogenic bacterium and belonging to the genus | 2014-11-27 |
20140348798 | SENECA VALLEY VIRUS BASED COMPOSITIONS AND METHODS FOR TREATING DISEASE - The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms. | 2014-11-27 |
20140348799 | NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - The present invention relates to a novel bacteriophage having a specific bactericidal activity against | 2014-11-27 |
20140348800 | MODIFIED TWO-COMPONENT GELATION SYSTEMS, METHODS OF USE AND METHODS OF MANUFACTURE - A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. A treatment agent, such as a cell type or a growth factor, can be added to either the first mixture or the second mixture. In some embodiments, the treatment agent is not added to either mixture. The first mixture can be co-injected with the second mixture to form a bioscaffolding in an infarct region for treatment thereof. | 2014-11-27 |
20140348801 | Treatment of Vocal Cords With Autologous Dermal Fibroblast Formulation - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three tunes approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×10 | 2014-11-27 |
20140348802 | METHODS OF TREATING ISCHEMIA - The invention provides compositions comprising stem and/or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and/or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia. | 2014-11-27 |
20140348803 | COMPOSITIONS AND METHODS FOR USING CELLS TO TREAT HEART TISSUE - This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue. | 2014-11-27 |
20140348804 | AGENT DERIVED FROM TORTOISE SPLEEN STIMULATING MAMMALIAN HEMOPOIESIS - The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them. | 2014-11-27 |
20140348805 | HIGH AFFINITY T CELL RECEPTOR AND USE THEREOF - The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen. | 2014-11-27 |
20140348806 | CELL-BASED THERAPY FOR THE PULMONARY SYSTEM - Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects. | 2014-11-27 |
20140348807 | PROCESS FOR THE PREPARATION OF A BIOMASS COMPRISING PLANTARICIN AND USES THEREOF IN MEDICAL FIELD - The present invention concerns methods for administering to a subject plantaricins A, N or K and/or a biomass having at least one plantaricin selected from plantaricins A. K or N or mixtures thereof and | 2014-11-27 |
20140348808 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHODS FOR THE PREPARATION AND USES THEREOF - The present invention relates to immunomodulatory cells, methods for providing immunomodulatory cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof. | 2014-11-27 |
20140348809 | COMPOSITIONS AND METHODS FOR GENERATING INTERLEUKIN-35-INDUCED REGULATORY T CELLS - Compositions and methods are provided for generating T cells having a regulatory phenotype from conventional T (T | 2014-11-27 |
20140348810 | ABSORBABLE IN SITU GEL-FORMING SYSTEM, METHOD OF MAKING AND USE THEREOF - An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and optionally one or more bioactive agent. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. The method of using in situ gel-forming composition for various applications is also disclosed. | 2014-11-27 |
20140348811 | COMPOSITIONS COMPRISING SUGAR-CYSTEINE PRODUCTS - The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same. | 2014-11-27 |
20140348812 | PROTOCOLS FOR TREATING AND PREVENTING OBESITY AND COMPLICATIONS ARISING THEREFROM - The present invention relates generally to the field of obesity and complications arising therefrom and in particular to the control of obesity by inhibiting adipogenesis and related processes. | 2014-11-27 |
20140348813 | THERMOSTABILIZATION OF PROTEINS - Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition. | 2014-11-27 |
20140348814 | ARGINNE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT - The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer. | 2014-11-27 |
20140348815 | SPRAY DRY METHOD FOR ENCAPSULATION OF BIOLOGICAL MOIETIES AND CHEMICALS IN POLYMERS CROSS-LINKED BY MULTIVALENT IONS FOR CONTROLLED RELEASE APPLICATIONS - Microencapsulation of bioactive and chemical cargo in a stable, cross-linked polymer matrix is presented that results in small particle sizes and is easily scaled-up for industrial applications. A formulation of a salt of an acid soluble multivalent ion, an acid neutralized with a volatile base and one or more monomers that cross-link in the presence of multivalent ions is atomized into droplets. Cross-linking is achieved upon atomization where the volatile base is vaporized resulting in a reduction of the pH of the formulation and the temporal release of multivalent ions from the salt that cross-link the monomers forming a capsule. The incorporation of additional polymers or hydrophobic compounds in the formulation allows control of hydration properties of the particles to control the release of the encapsulated compounds. The operational parameters can also be controlled to affect capsule properties such as particle-size and particle-size distribution. | 2014-11-27 |
20140348816 | USE OF COMPLEX FORMS OF CALMODULIN-LIKE SKIN PROTEIN CLSP - The invention also relates to the use of these complex forms for the purposes of screening for biological or chemical compounds capable of modulating a biological activity of said complex forms and/or for preparing and/or improving a pluristratified cell model. | 2014-11-27 |
20140348817 | COMPANION DIAGNOSTIC FOR ANTI-HYALURONAN AGENT THERAPY AND METHODS OF USE THEREOF - Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided. | 2014-11-27 |
20140348818 | BIOMARKERS OF KAWASAKI DISEASE - Biomarkers of Kawasaki Disease (KD) are provided. In certain aspects, methods are provided for detecting KD biomarkers, such as elevated PDGFC expression. Likewise, methods of treating a subject having a biomarker of KD are described. | 2014-11-27 |
20140348819 | Methods of Treating Cancer - The present invention provides methods of treating cancer. | 2014-11-27 |
20140348820 | IMMUNOGLOBULINS WITH REDUCED AGGREGATION - The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease. | 2014-11-27 |
20140348821 | Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer - Methods of testing to identify and to treat a subset of colon cancer patients exhibiting dMMR tumor tissue, who derive significant clinical benefit from the addition of bevacizumab to standard adjuvant chemotherapy. The presence of a V600E BRAF mutation is also of significance. | 2014-11-27 |
20140348822 | Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated DIseases - The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention. | 2014-11-27 |
20140348823 | Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer - The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer, hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of another chemotherapeutic agent, for example, another chemotherapeutic agent selected from: an antibody against VEGF, AVASTIN® (bevacizumab), an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount. | 2014-11-27 |
20140348824 | PREDICTIVE BIOMARKER OF SURVIVAL IN THE TREATMENT OF RENAL CELL CARCINOMA - Methods and compositions are disclosed for predicting and treating the clinical benefit to a human renal cell carcinoma patient prior to their treatment with a VEGFR inhibitor and an Ang2 inhibitor. | 2014-11-27 |
20140348825 | COMPOSITIONS AND METHODS TO MODULATE CELL ACTIVITY - The present invention provides methods and compositions for the remote control of cell function based on the use of radiofrequency waves to excite nanoparticles targeted to specific cell types. The nanoparticles may be applied to the target cell extracellularly and/or expressed intracellularly. The cell type of interest expresses a temperature sensitive channel wherein excitation of the nanoparticles results in a localized temperature increase that is transduced into a cellular response. Such cellular responses may include, for example, increases in gene expression resulting in production of one or more physiologically active proteins. The expression of such proteins can be used to treat a variety of different inherited or acquired diseases or disorders in a subject. Accordingly, the invention provides a generic approach for treatment of any disease associated with a protein deficiency. | 2014-11-27 |
20140348826 | ENGINEERING MULTIFUNCTIONAL AND MULTIVALENT MOLECULES WITH COLLAGEN XV TRIMERIZATION DOMAIN - The invention relates generally to a new trimerization domain useful for developing multifunctional and multivalent complexes. Particularly, the invention relates to the design of trimeric polypeptide complexes using polypeptide structural elements derived from the collagen XV protein, and their use in diagnostic and therapeutic systems in vivo and in vitro. The invention also relates to nucleic acids and vectors useful for producing said trimeric complexes. | 2014-11-27 |
20140348827 | VARIANT ACTIVIN RECEPTOR POLYPEPTIDES, ALONE OR IN COMBINATION WITH CHEMOTHERAPY, AND USES THEREOF - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 2014-11-27 |
20140348828 | INHIBITION OF SECRETION FROM NON-NEURONAL CELLS - The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells. | 2014-11-27 |
20140348829 | Felinized Antibodies and Methods of Treating Retroviral Infections in Felines - Provided are felinized antibodies and methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one felinized antibody or fragment thereof that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. | 2014-11-27 |